News & Updates
Filter by Specialty:
Fezolinetant reduces hot flashes during menopause
The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.
Fezolinetant reduces hot flashes during menopause
01 Aug 2022
Antenatal vitamin D supplementation may curb risk of infant eczema
Infants born to mothers who popped vitamin D during pregnancy are less likely to develop atopic eczema compared with their counterparts whose mothers received placebo, as shown in the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS).
Antenatal vitamin D supplementation may curb risk of infant eczema
01 Aug 2022
HBV coinfection among TB patients higher than expected
Coinfection with hepatitis B virus (HBV) among patients with tuberculosis (TB) appears to be 38-percent to 450-percent more prevalent than published estimates from the Polaris group of region-specific overall HBV prevalence, suggest the results of a meta-analysis.
HBV coinfection among TB patients higher than expected
01 Aug 2022
Men with multiple sclerosis at risk of erectile dysfunction
Adult men with multiple sclerosis (MS) are more likely to develop erectile dysfunction (ED), indicating that MS is a potential predictor for ED occurrence, suggest the results of a meta-analysis.
Men with multiple sclerosis at risk of erectile dysfunction
01 Aug 2022
HK’s first territory-wide long COVID study to inform follow-up care
Researchers at the Chinese University of Hong Kong (CUHK) have rolled out the city’s first territory-wide study of long COVID to inform multidisciplinary follow-up care for thousands of COVID-19 survivors. Participants are also invited to a second-phase 3-year prospective study of the impact of gut dysbiosis on long COVID symptoms and the potential role of gut microbiome modulation in treatment of long COVID.